KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Pacific Biosciences Of California (PACB) Net Income towards Common Stockholders (2016 - 2025)

Historic Net Income towards Common Stockholders for Pacific Biosciences Of California (PACB) over the last 16 years, with Q3 2025 value amounting to -$38.0 million.

  • Pacific Biosciences Of California's Net Income towards Common Stockholders rose 3742.28% to -$38.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$503.6 million, marking a year-over-year decrease of 2774.81%. This contributed to the annual value of -$309.9 million for FY2024, which is 101.59% down from last year.
  • Latest data reveals that Pacific Biosciences Of California reported Net Income towards Common Stockholders of -$38.0 million as of Q3 2025, which was up 3742.28% from -$41.9 million recorded in Q2 2025.
  • Over the past 5 years, Pacific Biosciences Of California's Net Income towards Common Stockholders peaked at $16.5 million during Q3 2021, and registered a low of -$426.1 million during Q1 2025.
  • In the last 5 years, Pacific Biosciences Of California's Net Income towards Common Stockholders had a median value of -$69.8 million in 2023 and averaged -$82.4 million.
  • In the last 5 years, Pacific Biosciences Of California's Net Income towards Common Stockholders skyrocketed by 16977.39% in 2021 and then tumbled by 56530.65% in 2022.
  • Quarter analysis of 5 years shows Pacific Biosciences Of California's Net Income towards Common Stockholders stood at -$69.3 million in 2021, then decreased by 21.72% to -$84.4 million in 2022, then grew by 2.8% to -$82.0 million in 2023, then soared by 102.89% to $2.4 million in 2024, then plummeted by 1702.7% to -$38.0 million in 2025.
  • Its Net Income towards Common Stockholders was -$38.0 million in Q3 2025, compared to -$41.9 million in Q2 2025 and -$426.1 million in Q1 2025.